Christopher Parsons

Christopher Parsons is an accomplished pharmacologist with extensive experience in neuropharmacology and drug development. Currently serving as Chief Pharmacologist and VP of Non-Clinical Development at Galimedix Therapeutics, Inc. since January 2019, Christopher also operated as a Senior Consultant from July 2017 to December 2018. Previously, Christopher held the position of Principal Scientific Expert in Pharmacology at Merz Pharmaceuticals for over 26 years, where responsibilities included leading the In Vitro Pharmacology department. Academic contributions include postdoctoral research at the Max Planck Institute for Psychiatry and Bristol Medical School, with a solid educational foundation featuring a Ph.D. and Privat Dozent in Neuropharmacology. Christopher's technical expertise encompasses a variety of methodologies, particularly in the fields of electrophysiology, molecular biology, and biochemistry.